Vivani Medical Inc. (VANI)

Over the past six months, Vivani Medical's stock has been impacted by common stock offerings, a business update and Q3 2025 financial results, the Cortigent spin-off, clinical study plans, and an analyst price target revision. The company announced the pricing and closing of common stock offerings in October 2025 and January 2026. In November 2025, Vivani Medical provided a business update and reported its third-quarter 2025 financial results, including the completion of the LIBERATE-1 study and positive preclinical data for NPM-139, showing 20% weight loss sustained for over seven months, which led to an 11.44% stock decline. Vivani Medical announced a planned spin-off of its Cortigent neuromodulation subsidiary, and Cortigent presented promising 6-year early feasibility study results for its Orion System in January 2026. The company has outlined plans to initiate a Phase 1 clinical study for its semaglutide implant program (NPM-139) in the first half of 2026, pending regulatory clearance. In December 2025, the average one-year price target for Vivani Medical was revised to $5.10 per share, an increase of 25.00% from a prior estimate. Over the past 52 weeks, VANI stock has traded between a low of $0.91 and a high of $1.92.

There is no specific information available indicating demand seasonality for Vivani Medical, Inc.'s products and services. Demand for its future products is likely to be driven by medical need and treatment efficacy rather than seasonal patterns.

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, long-acting drug implants for chronic diseases, utilizing its NanoPortal™ platform technology to create miniature, subdermal drug implants designed to deliver drug molecules steadily over extended periods. The company's primary product pipeline focuses on GLP-1-based implants for metabolic diseases, including NPM-115 (exenatide implant) for chronic weight management and type 2 diabetes, NPM-119 (exenatide implant) for type 2 diabetes, and NPM-139 (semaglutide implant) for chronic weight management. Vivani Medical also has a Neuromodulation Division and announced a planned spin-off of its Cortigent subsidiary, which develops brain implant devices.

Vivani Medical, Inc. is headquartered in Alameda, California, United States. The company has indicated an operational focus in Australia for its clinical studies, seeking regulatory clearance and leveraging research and development incentives from the Australian government.

Vivani Medical's brand reputation in the past year appears to be influenced by its clinical progress and analyst sentiment. Positive developments include positive preclinical weight loss data for its exenatide implant (NPM-115) and NPM-139, leading to a strategic focus on its obesity portfolio. Vivani Medical has received a consensus rating of "Hold" from analysts, with an average rating score of 2.00, and the average one-year price target for the stock has been increased. As a clinical-stage biopharmaceutical company, Vivani Medical faces inherent risks, including a current lack of revenue and reported losses, as well as concerns regarding future dilution, regulatory execution, and the clinical viability and commercial potential of its lead products.

Vivani Medical, Inc.'s ownership structure includes a mix of institutional, insider, and retail investors. As of December 2025, 32 institutional investors held positions in Vivani Medical, collectively owning 8.7% of the total outstanding shares, with major holders including Vanguard Group Inc., Tudor Investment Corp Et Al, Tanager Wealth Management LLP, Geode Capital Management, LLC, and BlackRock, Inc. Insiders hold a significant portion of the company's stock, approximately 51.64%, with Gregg Williams being the largest individual shareholder, holding 18.29 million shares, accounting for 30.87% of the total shares.